Enforcement Report - Week of February 1, 2023
Big high street pharmacy chains including Boots and Superdrug have run out of some hay fever medicines, with the manufacturer, GlaxoSmithKline, blaming temporary supply issues.
The first two of the month, issued to Celgene and Sanofi, addressed television advertisements the agency considered misleading. The medium was traditional; the reasoning potentially worrisome, according to pharma marketing experts. But since then, the agency has focused on digital communications—email, a webpage and two YouTube videos—and at least one of those hand-slaps raises questions about just how far the arm of the FDA can reach.
Anvisa Suspends (Paracetamol, Phenylephrine Hcl, Chlorpheniramine Maleate) Capsules Mfg by Brainfarma
G&C Natural Nutrition, Inc. Issues Voluntary Nationwide Recall of Pyrola Due to Undeclared Drug Ingredients
FDA raises alert on chinese drug for joint pain
Vernalis and Tris` Tuzistra (Codeine Polistirex and Chlorpheniramine Polistirex) Approved in USA For Cough
FDA Provides Generic Approval Roadmap for 38 Drugs, Including Vertex`s Kaldeco
Foreign Product Alert: Star Majestic Slimming, Sit and Slim II, Ginseng Kianpi Pil, Mayhem, Du Zhong Jin Gu Wan
Neos Therapeutics Announces Submission of a New Drug Application for its Methylphenidate Extended Release Oral Disintegrating Tablet XR ODT for the Treatment of ADHD